Thiazole tethered organoselenides as 5-lipoxygenase inhibitors
Thiazole tethered organoselenide compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The thiazole tethered organoselenide compounds are identified as being capable of inhibiting 5-lipoxygenase (5-LO).
1. A compound having the formula I:
or a pharmaceutically acceptable salt, ester, stereoisomer, or solvate thereof, wherein:
R is selected from the group consisting of
methyl, ethyl, butyl, pentyl, and hexyl; and
each X is the same or different and is H or COOMe.
2. The compound of claim 1 , wherein each X is H.
3. The compound of claim 1 , wherein each X is COOMe.
4. The compound of claim 1 , wherein:
R is methyl, ethyl, butyl, pentyl, and hexyl; and
X is H or COOMe.
5. The compound of claim 1 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt, ester, stereoisomer, or solvate thereof.
6. The compound of claim 1 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt, ester, stereoisomer, or solvate thereof;
wherein X is H or COOMe.
7. A pharmaceutically acceptable composition comprising a therapeutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.
8. A method of inhibiting 5-lipoxygenase (5-LO) activity in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1 .
9. The method of inhibiting 5-lipoxygenase (5-LO) activity in a patient of claim 8 , wherein administration of the compound to the patient treats asthma, a respiratory viral infection, or a combination thereof in the patient.
10. A method of treating asthma in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1 .
11. A method of treating a respiratory viral infection in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1 .
12. The method of treating a respiratory viral infection in a patient of claim 11 , wherein the respiratory viral infection is caused by COVID-19.
13. The method of treating a respiratory viral infection in a patient of claim 12 , wherein the administration of the compound reduces patient mortality rate, prevents COVID-19 progression, or prevents COVID-19 severity.
14. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt, ester, stereoisomer, or solvate thereof;
wherein X is H or COOMe.
15. A pharmaceutically acceptable composition comprising a therapeutically effective amount of the compound of claim 14 and a pharmaceutically acceptable carrier.
16. A method of inhibiting 5-lipoxygenase (5-LO) activity in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 14 .
17. The method of inhibiting 5-lipoxygenase (5-LO) activity in a patient of claim 16 , wherein administration of the compound to the patient treats asthma, a respiratory viral infection, or a combination thereof in the patient.